Paper Details

  1. Home
  2. Paper Details

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Author: Avila-ZapataFrancisco, CieślakDorota, FitzGeraldOliver, GrahamDaniela, HallStephen, HendrikxThijs, KanikKeith S, MeasePhilip, MenonSujatha, MerolaJoseph F, WangCunshan, van der HeijdeDésirée

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Tofacitinib was more effective than placebo in patients with psoriatic arthritis who had previously had an inadequate response to conventional synthetic DMARDs. The ACR20 response rates at month 3 were 50% in the 5-mg tofacitinib group and 61% in the 10-mg tofacitinib group, as compared with 33% in the placebo group. Adverse events were more frequent with tofacitinib than with placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic dru...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1615975

データ提供：米国国立医学図書館（NLM）

Psoriatic Arthritis: Tofacitinib and Adalimumab Offer Hope

Psoriatic arthritis is a chronic inflammatory disease that affects the joints and skin. This study evaluates the effectiveness of two medications, tofacitinib and adalimumab, compared to placebo in treating patients with active psoriatic arthritis who had previously had inadequate responses to conventional treatments.

The study found that both tofacitinib and adalimumab were significantly more effective than placebo in improving symptoms of psoriatic arthritis. The study also noted that both medications were associated with a higher rate of adverse events compared to placebo.

Tofacitinib and Adalimumab: Potential for Managing Psoriatic Arthritis

This study offers hope for patients with psoriatic arthritis, demonstrating the effectiveness of tofacitinib and adalimumab in managing symptoms. However, it is important to consider the potential side effects and discuss the risks and benefits with your healthcare provider.

Psoriatic Arthritis: A Journey Towards Relief

Psoriatic arthritis can be a challenging condition, impacting both physical and mental well-being. This study highlights the importance of exploring new treatment options and working with your doctor to find the right approach for managing your symptoms. Remember, the journey towards relief is often a process, and finding the right path takes time and patience.

Dr. Camel's Conclusion

Psoriatic arthritis can feel like wandering through a harsh desert, with symptoms that seem to stretch endlessly. This study provides a glimpse of hope, showing that tofacitinib and adalimumab can offer relief for many patients. While these medications may not be a perfect solution, they can be valuable tools in managing the condition, helping you navigate the desert and find a path towards greater comfort.

Date :
  1. Date Completed 2017-10-26
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

29045212

DOI: Digital Object Identifier

10.1056/NEJMoa1615975

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.